Ranolazine for the suppression of ventricular arrhythmia: A case series

Annals of Noninvasive Electrocardiology

Volumn 19, Issue 4, 2014, Pages 345-350

  Yeung, Eric ^a   Krantz, Mori J ^b,c,d   Schuller, Joseph L ^b,c   Dale, Rita A ^d   Haigney, Mark C ^a,e  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d CPC Clinical Research   (United States)

^e Uniformed Services University of the Health Sciences   (United States)

Author keywords

implantable cardioverter defibrillator; premature ventricular complex; ranolazine; sodium channel; ventricular arrhythmia; ventricular tachycardia

Indexed keywords

RANOLAZINE; ACETANILIDE DERIVATIVE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CASE STUDY; CATHETER ABLATION; CLINICAL ARTICLE; DEFIBRILLATOR; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MALE; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; NONISCHEMIC CARDIOMYOPATHY; PREMATURE VENTRICULAR COMPLEX; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CASE REPORT; CLINICAL TRIAL; MULTICENTER STUDY; PATHOPHYSIOLOGY; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR PREMATURE COMPLEXES;

ACETANILIDES; ADULT; AGED; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RETROSPECTIVE STUDIES; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR PREMATURE COMPLEXES;

EID: 84904624708     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/anec.12137     Document Type: Article

References (18)

1. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010; 7 (7): 865-869.
2. Moss AJ, Schuger C, Beck CA, et al. MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367 (24): 2275-2283.
3. The cardiac arrhythmia suppression trial. N Engl J Med 1989; 321 (25): 1754-176.
4. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 2009; 6 (6): 886-933.
5. Antzelevitch C, Burashnikov A, Sicouri S, et al. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011; 8: 1281-1290.
6. 2+ overload and inhibited by ranolazine. J Mol Cell Cardiol 2009; 47 (2): 326-334.
7. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. J Am Med Assoc 2007; 297 (16): 1775-1783.
8. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116 (15): 1647-1652.
9. Nanda S, Levin V, Martinez MW, et al. Ranolazine treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy. Pacing Clin Electrophysiol 2010; 33 (12): e119-120.
10. Kaliebe JW, Murdock DK,. Suppression of non-sustained ventricular tachycardia with ranolazine: A case report. Wisc Med J 2009; 108 (7): 373-375.
11. Bunch TJ, Manapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol 2011; 34 (12): 1600-1606.
12. Belhassen B, Viskin S,. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol 1993; 4: 356-358.
13. Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005; 45: 1259-1265.
14. Lerman BB, Stein KM, Engelstein ED, et al. Mechanism of repetitive monomorphic ventricular tachycardia. Circulation 1995; 92: 421-429.
15. Iwai S, Cantillon DJ, Kim RJ, et al. Right and left ventricular outflow tract tachycardias: Evidence for a common electrophysiologic mechanism. J Cardiovasc Electrophysiol 2006; 17 (10): 1052-1058.
16. Ono K, Fozzard HA, Hanck DA,. A direct effect of forskolin on sodium channel bursting. Pflugers Arch 1995; 429 (4): 561-569.
17. Maltsev VA, Silverman N, Sabbah HN, et al. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: Implications for repolarization variability. Eur J Heart Fail 2007; 9 (3): 219-227.
18. Pogwizd SM, McKenzie JP, Cain ME,. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 1998; 98 (22): 2404-2414.